证券代码：301101 证券简称：明月镜片 公告编号：2025-012 明月镜片股份有限公司 关于召开公司 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开的第 二届董事会第十七次会议审议通过了《关于召开公司 2024 年年度股东大会的议 案》，决定于 2025 年 5 月 13 日（星期二）14:30 召开 2024 年年度股东大会，现 将有关事项通知如下： 一、会议召开的基本情况 （一）会议届次：2024 年年度股东大会 （二）会议召集人：董事会。公司第二届董事会第十七次会议于 2025 年 4 月 16 日召开，审议通过了《关于召开公司 2024 年年度股东大会的议案》，同意 召开本次股东大会。 （三）会议召开的合法性及合规性：本次董事会召开股东大会会议符合有关 法律、行政法规、部门规章、规范性文件和《公司章程》的相关规定。 （四）会议召开日期、时间： 1、会议召开时间：2025 年 5 月 13 日（星期二）14:30 2、网络投票时间：202 ...

证券代码：301101 证券简称：明月镜片 公告编号：2025-003 明月镜片股份有限公司 第二届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届监事会第十七次会议于 2025 年 4 月 16 日在公司会议室以现场表决方式召开。本次会议通知于 2025 年 4 月 4 日以专人送达、电话、微信等形式通知了全体监事。本次会议由监事会主 席朱海峰先生召集并主持，应出席公司会议的监事 3 人，实际出席公司会议的监 事 3 人。会议召开符合《中华人民共和国公司法》、《公司章程》等规定，会议合 法有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年年度报告的程序符合 法律、行政法规和中国证监会的规定，年报内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 3 票，反对 0 票 ...

证券代码：301101 证券简称：明月镜片 公告编号：2025-002 明月镜片股份有限公司 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届董事会第十七次会议于 2025 年 4 月 16 日在公司会议室以现场结合通讯的表决方式召开。本次会议通知于 2025 年 4 月 4 日以专人送达、电话、微信的方式通知了全体董事。本次会议由董事长谢 公晚先生主持，应出席会议董事 7 人，实际参加会议董事 7 人，公司监事、高级管 理人员列席会议。会议召开符合《中华人民共和国公司法》、《公司章程》等规定， 会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 公司董事会战略与投资委员会和审计委员会审议通过了上述议案。 表决结果：7 票同意；0 票反对；0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的 ...

Financial Performance - The company's operating revenue for 2024 reached ¥770,297,786.61, an increase of 2.88% compared to ¥748,743,207.89 in 2023[18] - Net profit attributable to shareholders for 2024 was ¥176,785,928.28, reflecting a growth of 12.21% from ¥157,543,021.14 in 2023[18] - The basic earnings per share for 2024 was ¥0.8807, up 12.65% from ¥0.7818 in 2023[18] - The total assets at the end of 2024 amounted to ¥1,861,102,531.56, a 6.18% increase from ¥1,752,743,944.92 at the end of 2023[18] - The cash flow from operating activities for 2024 was ¥211,159,110.55, a slight increase of 0.99% from ¥209,092,426.97 in 2023[18] - The company reported a weighted average return on equity of 10.99% for 2024, compared to 10.33% in 2023[18] - The net profit after deducting non-recurring gains and losses for 2024 was ¥152,097,603.69, an increase of 11.67% from ¥136,198,456.01 in 2023[18] - The gross profit margin improved to 58.56%, an increase of 0.98 percentage points compared to the previous year[79] - The sales of the "Easy Control" series products in 2024 amounted to 163.65 million yuan, reflecting a year-on-year growth of 22.7%[79] - The "PMC Ultra Bright" series saw a revenue increase of nearly 45.6% in 2024 compared to the previous year[79] Market Position and Opportunities - The company holds a leading position in the Chinese lens market with a retail market share of 12.4% as of 2024, according to Frost & Sullivan[27] - The number of myopic individuals in China increased from 540 million in 2016 to 660 million in 2020, with the overall myopia rate rising from 39.2% to 47.1%[28] - The government has implemented multiple policies since 2018 to promote myopia prevention and control among children and adolescents, indicating a growing market opportunity for the company[28] - By the end of 2024, the elderly population aged 60 and above in China is projected to reach 310.31 million, accounting for 22% of the total population, driving demand for progressive multifocal lenses[29] - The Chinese eyewear market is projected to grow from CNY 958.3 billion in 2024 to CNY 1,283 billion by 2029, with a CAGR of 5.0% from 2019 to 2024 and 6.0% from 2024 to 2029[30] Product Development and Innovation - The company has developed high-quality lens materials that are 5.6 times more impact-resistant than standard lenses, enhancing user comfort and visual quality[36] - The company launched a new shallow blue light blocking lens product in April 2024, expanding its product matrix to meet diverse user needs[37] - The company’s myopia control lenses utilize proprietary resin materials and unique processes, offering better optical performance and durability compared to competitors[38] - The new generation of "Easy Control PRO2.0" lenses has improved the effective rate of equivalent spherical power to 73.82%, up from 60% in PRO1.0, based on a 12-month clinical trial[39] - The upgraded "1.74" high-index lenses provide a maximum power selection of 1500 degrees, reducing lens thickness and weight for enhanced comfort[39] Sales and Distribution - The company's direct sales revenue reached 442.35 million yuan, accounting for 57.43% of total revenue, while distribution channel revenue was 264.63 million yuan, making up 34.35% of total revenue[55] - The company has established a sales network with 2,707 direct sales clients and 66 distribution clients as of the end of 2024, optimizing its customer structure[55] - Domestic sales accounted for 96.21% of total revenue, with a year-on-year increase of 4.63%[81] Research and Development - The company has 108 R&D personnel, enhancing its research capabilities[78] - R&D expenses rose by 24.96% to 34.99 million yuan, indicating a strong focus on innovation[90] - The company has established partnerships with leading universities and research institutions to develop new technologies and materials[76] - The company is committed to continuous product innovation and aims to launch new products and technologies to create differentiated offerings in the market[141] Corporate Governance and Management - The company operates independently from its controlling shareholders and has a complete business system for supply, production, and sales[154] - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[154] - The company has established independent financial and operational management systems, ensuring no shared bank accounts with controlling shareholders[159] - The company has a well-structured internal management system, with no mixed operations with controlling shareholders[159] Social Responsibility and Brand Building - The company has actively contributed to myopia prevention efforts, including public service campaigns that have aired on national television[58] - The company has partnered with the Chinese Mountaineering Team and the Chinese space program, enhancing its brand recognition and commitment to social responsibility[57] - The company is actively involved in public welfare initiatives to raise awareness about eye health among children and adolescents[125] Future Plans and Strategic Initiatives - Future plans include increased R&D investment in new technologies such as AI smart glasses, focusing on enhancing operational quality[47] - The company plans to expand its product matrix to "1+3+N" by 2025, focusing on the "轻松控 Pro2.0" series and introducing new high-refractive index products[133] - The company aims to enhance brand trust by establishing a team of 100 ophthalmology experts to provide professional endorsement and support[134] Financial Management and Fundraising - The company reported an investment amount of RMB 3,215,000,000 for the current period, representing a 48.43% increase compared to RMB 2,166,000,000 in the same period last year[102] - The total amount of funds raised was RMB 903,783,114, with a net amount of RMB 792,923,877 after deducting various issuance costs[106] - The company has committed to several investment projects, including high-end resin lens production expansion, with a total investment commitment of RMB 30,000,000[109] Employee Development and Training - The total number of employees at the end of the reporting period was 1,068, including 945 at the parent company and 123 at major subsidiaries[185] - The company has established a series of training programs focused on key positions to enhance business and management capabilities[188] - The company has implemented a differentiated salary adjustment strategy for key positions to ensure compensation competitiveness above the industry median[186]

Financial Performance - The company's revenue for Q1 2025 was CNY 197,143,516.30, representing a 2.63% increase compared to CNY 192,086,337.15 in the same period last year[5]. - Net profit attributable to shareholders increased by 11.70% to CNY 47,147,755.44 from CNY 42,208,439.85 year-on-year[5]. - The total operating revenue for the current period is CNY 197,143,516.30, an increase from CNY 192,086,337.15 in the previous period, reflecting a growth of approximately 2.2%[25]. - The company reported a net profit of CNY 51,299,148.60 for the current period, compared to CNY 42,819,783.73 in the previous period, indicating an increase of around 19.8%[25]. - The net profit for the current period is 49,540,791.48, an increase of 11.8% compared to 44,455,356.74 in the previous period[26]. - The total profit for the current period is 56,832,700.50, up from 51,475,060.92, reflecting a growth of 10.5%[26]. - Basic and diluted earnings per share increased to 0.2349 from 0.2103, representing an increase of 11.8%[27]. - The overall business gross margin for Q1 2025 was 58.42%, an increase of 0.35 percentage points compared to the same period last year[16]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 70.63%, amounting to CNY 6,407,779.49 compared to CNY 21,818,792.00 in the previous year[5]. - Cash flow from operating activities generated a net amount of 6,407,779.49, down from 21,818,792.00, indicating a decline of 70.7%[28]. - Cash flow from investing activities resulted in a net outflow of -1,159,560,442.61, worsening from -613,217,427.29 in the previous period[29]. - Cash and cash equivalents decreased to CNY 120,003,686.80 from CNY 1,288,022,229.66, a significant decline of approximately 90.7%[21]. - Cash and cash equivalents at the end of the period decreased to 120,003,686.80 from 481,825,413.16, a decline of 75.1%[29]. - The total assets at the end of the reporting period were CNY 1,945,602,988.04, a 4.54% increase from CNY 1,861,102,531.56 at the end of the previous year[5]. - The total assets increased to CNY 1,945,602,988.04 from CNY 1,861,102,531.56, reflecting a growth of about 4.5%[23]. Liabilities and Expenses - The total liabilities increased to CNY 179,646,168.90 from CNY 144,686,738.94, representing a rise of about 24.2%[23]. - The cash and cash equivalents decreased to CNY 120,003,686.80 from CNY 1,288,022,229.66, a significant decline of approximately 90.7%[21]. - The total operating costs decreased to CNY 145,844,367.70 from CNY 149,266,553.42, representing a reduction of about 2.9%[25]. - The company incurred a tax expense of 7,291,909.02, slightly up from 7,019,704.18, reflecting a rise of 3.9%[26]. Research and Development - Research and development expenses rose by 37.53% to CNY 9,526,927.93 from CNY 6,926,956.54 year-on-year, indicating increased investment in innovation[11]. - Research and development expenses increased to CNY 9,526,927.93 from CNY 6,926,956.54, showing a growth of approximately 37.8%[25]. - The company plans to continue increasing R&D investment to drive product innovation and maintain a competitive edge in the market[19]. Product and Market Development - The company is focusing on developing differentiated products and advancing industry-leading technologies to enhance market competitiveness[19]. - The company launched a series of new high-refractive index products in Q1 2025 to meet diverse consumer needs[18]. - The new 1.67 refractive index added to the PMC Ultra Bright series caters to different myopia levels, enhancing both clarity and aesthetics[18]. - The company is focusing on customized marketing support for top 100 clients to improve brand awareness and customer acquisition efficiency[17]. - The demand for functional and high-refractive index products is increasing among younger consumers, driving innovation in the smart eyewear market[17]. - The company's lens business grew by 5% year-on-year in Q1 2025, excluding the negative impact from overseas and raw material businesses[16]. - Revenue from the PMC Ultra Bright series increased by 44% in Q1 2025, with three star products accounting for 57% of total revenue from regular lenses[16]. - Sales of the "Easy Control" series reached 50.13 million yuan in Q1 2025, representing a year-on-year growth of 22.1%[16]. - The "Easy Control" series sales for 2024 are projected to reach 54.96 million yuan, reflecting a year-on-year growth of 33.8%[16]. - The company aims to provide comprehensive eye health solutions by continuously optimizing product performance and service quality[17]. Accounts Receivable - The company reported a significant increase in accounts receivable by 59.27%, reaching CNY 173,839,579.72, attributed to increased sales and outstanding credit sales[11]. Borrowings - The company has undertaken a special loan, resulting in a 100% increase in long-term borrowings to CNY 26,876,509.71[11]. Other Income - The company recorded a total of CNY 5,571,395.96 in non-recurring gains, primarily from government subsidies and financial asset disposals[7]. Cash Flow from Investment Activities - The company experienced a 89.09% increase in net cash flow from investment activities, amounting to CNY -1,159,560,442.61, due to changes in investment product terms[11].

证券代码：301101 证券简称：明月镜片 公告编号：2025-004 明月镜片股份有限公司 关于公司 2024 年度利润分配预案的公告 利润分配方案符合《上市公司监管指引第 3 号——上市公司现金分红（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规有关分红的规定，与《公司章程》规定的利润分配政策和 公司已披露的股东回报规划不存在重大差异。 三、现金分红方案的具体情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 明月镜片股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开了第 二届董事会审计委员会第十四次会议、第二届董事会第十七次会议及第二届监事 会第十七次会议，审议通过了《关于公司 2024 年度利润分配预案的议案》，本 议案尚需提交公司股东大会审议。董事会审计委员会、董事会及监事会均认为本 次利润分配符合《公司法》、《公司章程》等相关法律法规的要求，符合公司的 实际情况，对公司生产经营无重大影响，有利于股东实现回报，符合全体股东的 利益。 二、利润分配方案 经立 ...

Investment Rating - The industry investment rating is "Recommended (Maintain)" [1] Core Viewpoints - The light industry sector is expected to become a significant node in the AI industry chain, with various sub-sectors such as eyewear and toys already implementing AI applications. Companies deeply involved in the AI supply chain are likely to benefit from future industry growth [9][3]. - Specific sub-sectors benefiting from AI include eyewear, mattresses, sports, and toys, which are recommended for investment focus [3][9]. Summary by Sections AI Eyewear - AI eyewear is entering a product explosion phase, with significant market response to products like Ray Ban Meta, which achieved a quarterly sales volume of 680,000 units in Q4 2024. Global sales of AI eyewear are projected to reach 1.5 million units in 2024, a year-on-year increase of 533% [17][20]. - The market for AI eyewear is dominated by models with cameras, accounting for 94% of sales, primarily driven by the success of Ray Ban Meta [21][23]. - The cost structure of AI eyewear shows that lenses and frames account for about 8% of the total cost, with potential for significant value enhancement through advanced technologies [28][29]. AI Mattresses - AI mattresses integrate AI technology to monitor sleep data and adjust firmness and support based on user needs, addressing the growing sleep issues in modern society. The global market for AI mattresses was approximately $1.7 billion in 2023, with a projected CAGR of 5.6% from 2024 to 2030 [44][46]. - The market is still in its early stages, with intense competition and a focus on consumer education to enhance awareness and acceptance of AI mattress technology [48][50]. AI Sports and Fitness - The AI sports fitness market is characterized by two business models: one targeting consumers through apps and equipment, and the other targeting gyms with AI fitness devices. The market is expected to grow rapidly, with the Chinese smart fitness market projected to reach 82 billion yuan by 2025 [65][66]. - The penetration of AI fitness solutions is low but growing, with significant potential for expansion as consumer awareness increases and technology becomes more accessible [63][66].

东方证券股份有限公司 关于明月镜片股份有限公司 2024 年持续督导现场检查报告 | 保荐机构名称：东方证券股份有限公司 | 被保荐公司简称：明月镜片 | | | | --- | --- | --- | --- | | 保荐代表人姓名：郑睿 | 联系电话：021-2315 3548 | | | | 保荐代表人姓名：温畅 | 联系电话：021-2315 3966 | | | | 现场检查人员姓名：温畅 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2025 年 3 月 7 日 | | | | | 一、现场检查事项 现场检查意见 | | | | | （一）公司治理 否 不适用 | | 是 | | | 现场检查手段：（1）查阅公司章程及内部控制制度；（2）查阅公司历次董事会、监事会、股东大会材料；（3） | | | | | 与公司相关人员进行访谈沟通 | | | | | 1.公司章程和公司治理制度是否完备、合规 | | 是 | | | 2.公司章程和三会规则是否得到有效执行 | | 是 | | | 3.三会会议记录是否完整，时间、地点、出席人员及会议内容等要件是否齐备， | ...

东方证券股份有限公司 关于明月镜片股份有限公司 持续督导现场培训报告 深圳证券交易所： 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为明月 镜片股份有限公司（以下简称"明月镜片"或"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《深圳证券交易所上市公司自律监管指引第 13 号 ——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》的要求，对公司实际控制人及董事、监事、高级管理人员进行了 培训，现将培训情况报告如下： 三、本次培训的内容 本次培训的内容主要包括：创业板上市公司再融资相关政策；上市公司规范 运作和上市公司董事、监事、高级管理人员的行为规范；上市公司违法典型案例。 四、本次培训的成果 一、本次培训的基本情况 2025 年 3 月 7 日，东方证券保荐代表人温畅对公司实际控制人及董事、监 事、高级管理人员进行了培训。 二、参加本次培训的人员 公司实际控制人及董事、监事、高级管理人员。 （以下无正文） （此页无正文，为《东方证券股份有限公司关于明月镜片股份有限公司持 续督导现场培训报告》之签字盖章页） 保荐代表人签名： 郑 睿 温 畅 东方证 ...